...said Dominic Smethurst joined as CMO, a new position. Previously, he held the same role at Tusk Therapeutics...

...Viracta Therapeutics Inc. as CMO, effective May 1. Smethurst was the group medical director at Tusk Therapeutics Ltd....

...see "Volastra Raises $12M Seed to Shut Down Metastasis" ). Dochez was previously CEO of Tusk Therapeutics...

...The December deal came just over a year after Roche took out another IL-2 company, Tusk Therapeutics Ltd....

...Cancer Miss” ; “Lilly Shells Out for Armo” ). It also dwarfs the price of Tusk Therapeutics Ltd....

...NSCLC) and urothelial cancer. In another deal announced Sept. 28, Roche acquired cancer immunotherapy company Tusk Therapeutics Ltd....

...NSCLC) and urothelial cancer. In another deal announced Sept. 28, Roche acquired cancer immunotherapy company Tusk Therapeutics Ltd....

...Intelligence Buyer Seller Date U/F cash ($M) Milestones ($M) Disclosed value ($M) Roche (SIX:ROG; OTCQX:RHHBY) Tusk Therapeutics Ltd....

...Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up...
...Black Belt's initial chairman, told BioCentury that the spinout will largely maintain Tusk's management team. Tusk Therapeutics Ltd....
...Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech Inc. Roche Tusk Therapeutics Ltd. CD38 Interleukin-2...

...Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up...
...Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech Inc. Roche Tusk Therapeutics Ltd. CD38 Interleukin-2...